In Vitro Diagnostics Market (Technology Type: Point-of-care, Molecular Diagnostics, Immunoassays, Clinical Chemistry, Whole Blood Glucose Monitoring, Hematology, Clinical Microbiology, Coagulation & Hemostasis, and Others; Application: Drug Testing, Infectious Diseases, Oncology, Metabolic Diseases, Autoimmune Diseases, and Others; and End-user: Diagnostic Laboratories, Hospitals, Academic & Research Centers, Home Care, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global In Vitro Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Application Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global In Vitro Diagnostics Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Mergers and Acquisition
5.2. Key Success Factor for Top 3 Players
5.3. Regulatory Scenario
5.4. Technology Assessment
6. Global In Vitro Diagnostics Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value & Volume Forecast, by Application, 2017–2030
6.3.1. Drug Testing
6.3.2. Infectious Diseases
6.3.3. Oncology
6.3.4. Metabolic Diseases
6.3.5. Autoimmune Diseases
6.3.6. Others
6.4. Market Attractiveness Analysis, by Application
7. Global In Vitro Diagnostics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value & Volume Forecast, by End-user, 2017–2030
7.3.1. Diagnostic Laboratories
7.3.2. Hospitals
7.3.3. Academic & Research Centers
7.3.4. Home Care
7.3.5. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global In Vitro Diagnostics Market Analysis and Forecast, by Technology Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value & Volume Forecast, by Technology Type, 2017–2030
8.3.1. Point-of-care
8.3.2. Molecular Diagnostics
8.3.3. Immunoassays
8.3.4. Clinical Chemistry
8.3.5. Whole Blood Glucose Monitoring
8.3.6. Hematology
8.3.7. Clinical Microbiology
8.3.8. Coagulation & Hemostasis
8.3.9. Others
8.4. Market Attractiveness Analysis, by Technology Type
9. Global In Vitro Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value & Volume Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America In Vitro Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Application, 2017–2030
10.2.1. Drug Testing
10.2.2. Infectious Diseases
10.2.3. Oncology
10.2.4. Metabolic Diseases
10.2.5. Autoimmune Diseases
10.2.6. Others
10.3. Market Value & Volume Forecast, by End-user, 2017–2030
10.3.1. Diagnostic Laboratories
10.3.2. Hospitals
10.3.3. Academic & Research Centers
10.3.4. Home Care
10.3.5. Others
10.4. Market Value & Volume Forecast, by Technology Type, 2017–2030
10.4.1. Point-of-care
10.4.2. Molecular Diagnostics
10.4.3. Immunoassays
10.4.4. Clinical Chemistry
10.4.5. Whole Blood Glucose Monitoring
10.4.6. Hematology
10.4.7. Clinical Microbiology
10.4.8. Coagulation & Hemostasis
10.4.9. Others
10.5. Market Value & Volume Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Application
10.6.2. By End-user
10.6.3. By Technology Type
10.6.4. By Country
11. Europe In Vitro Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Application, 2017–2030
11.2.1. Drug Testing
11.2.2. Infectious Diseases
11.2.3. Oncology
11.2.4. Metabolic Diseases
11.2.5. Autoimmune Diseases
11.2.6. Others
11.3. Market Value & Volume Forecast, by End-user, 2017–2030
11.3.1. Diagnostic Laboratories
11.3.2. Hospitals
11.3.3. Academic & Research Centers
11.3.4. Home Care
11.3.5. Others
11.4. Market Value & Volume Forecast, by Technology Type, 2017–2030
11.4.1. Point-of-care
11.4.2. Molecular Diagnostics
11.4.3. Immunoassays
11.4.4. Clinical Chemistry
11.4.5. Whole Blood Glucose Monitoring
11.4.6. Hematology
11.4.7. Clinical Microbiology
11.4.8. Coagulation & Hemostasis
11.4.9. Others
11.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Application
11.6.2. By End-user
11.6.3. By Technology Type
11.6.4. By Country/Sub-region
12. Asia Pacific In Vitro Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Application, 2017–2030
12.2.1. Drug Testing
12.2.2. Infectious Diseases
12.2.3. Oncology
12.2.4. Metabolic Diseases
12.2.5. Autoimmune Diseases
12.2.6. Others
12.3. Market Value & Volume Forecast, by End-user, 2017–2030
12.3.1. Diagnostic Laboratories
12.3.2. Hospitals
12.3.3. Academic & Research Centers
12.3.4. Home Care
12.3.5. Others
12.4. Market Value & Volume Forecast, by Technology Type, 2017–2030
12.4.1. Point-of-care
12.4.2. Molecular Diagnostics
12.4.3. Immunoassays
12.4.4. Clinical Chemistry
12.4.5. Whole Blood Glucose Monitoring
12.4.6. Hematology
12.4.7. Clinical Microbiology
12.4.8. Coagulation & Hemostasis
12.4.9. Others
12.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Application
12.6.2. By End-user
12.6.3. By Technology Type
12.6.4. By Country/Sub-region
13. Latin America In Vitro Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value & Volume Forecast, by Application, 2017–2030
13.2.1. Drug Testing
13.2.2. Infectious Diseases
13.2.3. Oncology
13.2.4. Metabolic Diseases
13.2.5. Autoimmune Diseases
13.2.6. Others
13.3. Market Value & Volume Forecast, by End-user, 2017–2030
13.3.1. Diagnostic Laboratories
13.3.2. Hospitals
13.3.3. Academic & Research Centers
13.3.4. Home Care
13.3.5. Others
13.4. Market Value & Volume Forecast, by Technology Type, 2017–2030
13.4.1. Point-of-care
13.4.2. Molecular Diagnostics
13.4.3. Immunoassays
13.4.4. Clinical Chemistry
13.4.5. Whole Blood Glucose Monitoring
13.4.6. Hematology
13.4.7. Clinical Microbiology
13.4.8. Coagulation & Hemostasis
13.4.9. Others
13.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Application
13.6.2. By End-user
13.6.3. By Technology Type
13.6.4. By Country/Sub-region
14. Middle East & Africa In Vitro Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value & Volume Forecast, by Application, 2017–2030
14.2.1. Drug Testing
14.2.2. Infectious Diseases
14.2.3. Oncology
14.2.4. Metabolic Diseases
14.2.5. Autoimmune Diseases
14.2.6. Others
14.3. Market Value & Volume Forecast, by End-user, 2017–2030
14.3.1. Diagnostic Laboratories
14.3.2. Hospitals
14.3.3. Academic & Research Centers
14.3.4. Home Care
14.3.5. Others
14.4. Market Value & Volume Forecast, by Technology Type, 2017–2030
14.4.1. Point-of-care
14.4.2. Molecular Diagnostics
14.4.3. Immunoassays
14.4.4. Clinical Chemistry
14.4.5. Whole Blood Glucose Monitoring
14.4.6. Hematology
14.4.7. Clinical Microbiology
14.4.8. Coagulation & Hemostasis
14.4.9. Others
14.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Application
14.6.2. By End-user
14.6.3. By Technology Type
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Market Footprint Analysis
15.3.1. By Region
15.3.2. By Application Type
15.4. Competitive Business Strategies
15.5. Company Profiles
15.5.1. Competition Matrix
15.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.1.2. Product Portfolio
15.5.1.3. SWOT Analysis
15.5.1.4. Strategic Overview
15.5.2. F. Hoffmann-La Roche Ltd.
15.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.2.2. Product Portfolio
15.5.2.3. SWOT Analysis
15.5.2.4. Strategic Overview
15.5.3. Danaher
15.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.3.2. Product Portfolio
15.5.3.3. SWOT Analysis
15.5.3.4. Strategic Overview
15.5.4. Siemens Healthineers
15.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.4.2. Product Portfolio
15.5.4.3. SWOT Analysis
15.5.4.4. Strategic Overview
15.5.5. bioMérieux SA
15.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.5.2. Product Portfolio
15.5.5.3. SWOT Analysis
15.5.5.4. Strategic Overview
15.5.6. Abbott
15.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.6.2. Product Portfolio
15.5.6.3. SWOT Analysis
15.5.6.4. Strategic Overview
15.5.7. Diasorin
15.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.7.2. Product Portfolio
15.5.7.3. SWOT Analysis
15.5.7.4. Strategic Overview
15.5.8. Meridian Bioscience, Inc.
15.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.8.2. Product Portfolio
15.5.8.3. SWOT Analysis
15.5.8.4. Strategic Overview
15.5.9. Ortho-Clinical Diagnostics, Inc.
15.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.9.2. Product Portfolio
15.5.9.3. SWOT Analysis
15.5.9.4. Strategic Overview
15.5.10. Thermo Fisher Scientific, Inc.
15.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.10.2. Product Portfolio
15.5.10.3. SWOT Analysis
15.5.10.4. Strategic Overview
15.5.11. Sysmex Corporation
15.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.11.2. Product Portfolio
15.5.11.3. SWOT Analysis
15.5.11.4. Strategic Overview
15.5.12. Other Prominent Players
15.5.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.5.12.2. Product Portfolio
15.5.12.3. SWOT Analysis
15.5.12.4. Strategic Overview